Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma

J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA

Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing

IOL Chemicals and Pharmaceuticals bags EcoVadis silver medal

Ranks among the top 15% companies globally

Evertis selects Honeywell Aclar technology to enhance pharmaceutical packaging

Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Globally, BRUKINSA is approved in more than 70 countries

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP

Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr

IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025